Diphencyprone - RXi Pharmaceuticals

Drug Profile

Diphencyprone - RXi Pharmaceuticals

Alternative Names: Diphenylcyclopropenone; Samcyprone

Latest Information Update: 23 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hapten Pharmaceuticals
  • Developer Hapten Pharmaceuticals; RXi Pharmaceuticals
  • Class Allergens; Antiallergics; Cyclopropanes; Haptens; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alopecia areata; Cancer metastases; Warts

Highest Development Phases

  • Phase II Alopecia areata; Cancer metastases; Warts

Most Recent Events

  • 18 May 2018 Efficacy and adverse enevts data from a phase IIa trial in Warts released by RXi Pharmaceuticals
  • 16 Jan 2018 Diphencyprone - RXi Pharmaceuticals is available for licensing as of 16 Jan 2018. http://www.rxipharma.com
  • 14 Sep 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top